ResultsIQ

ResultsIQ › Latest results › Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited Q2 FY27 results deck summary

NSE: EMCURE · BSE: 544210

Results deck of 3 Nov 2026, summarised by AI from the filing.

Q2 FY27 revenue ₹28,205 cr, up 24.3% YoY, with EBITDA margin 20.4% and PAT ₹3,251 cr, up 29.3%.

Key takeaways

  1. Domestic outlook Management expects continued domestic growth over the full year as the strengthened team and portfolio gain traction.
  2. Domestic acceleration Domestic growth improved from 10% in Q1 FY27 to 12% in Q2 FY27, the second consecutive quarter of double-digit growth.
  3. International growth International revenue rose 34.5% YoY to ₹16,652 cr, led by Europe, Canada and RoW new launches and approvals.
  4. Net debt Net debt rose to ₹13,171 cr on Mantra earnout and Gennova consolidation payments.

Original filing on BSE

Emcure Pharmaceuticals Limited Q2 FY27 results

As filed: Revenue ₹2,820 cr (+24% year on year), EBITDA ₹588 cr (+24% year on year), PAT ₹325 cr (+30% year on year), EBITDA margin 20.8% (−13 bps).

The Q2 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹2,580 cr (+23% year on year), EBITDA ₹533 cr (+28% year on year), PAT ₹292 cr (+36% year on year), EBITDA margin 20.6% (+79 bps). Score 66 of 100, Above trend. Revenue growth was well above the company's own trend; EBITDA and profit growth were in line with it. EBITDA margin rose 79 bps year on year. Revenue rose ₹479 cr on a year ago, more than the ₹286 cr it added the year before. Share price after the results: −1.6% in 29 days (Nifty 500: −2.0%).
  • Q4 FY26: Revenue ₹2,470 cr (+17% year on year), EBITDA ₹480 cr (+19% year on year), PAT ₹244 cr (+24% year on year), EBITDA margin 19.4% (+37 bps). Score 63 of 100, In line with trend. EBITDA margin rose 37 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −2.7% in 30 days (Nifty 500: −1.5%).
  • Q3 FY26: Revenue ₹2,363 cr (+20% year on year), EBITDA ₹493 cr (+39% year on year), PAT ₹231 cr (+53% year on year), EBITDA margin 20.9% (+276 bps). Score 82 of 100, Above trend. EBITDA margin rose 276 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −6.0% in 30 days (Nifty 500: −4.1%).
  • Q2 FY26: Revenue ₹2,270 cr (+13% year on year), EBITDA ₹476 cr (+25% year on year), PAT ₹251 cr (+24% year on year), EBITDA margin 21.0% (+199 bps). Score 66 of 100, Above trend. EBITDA margin rose 199 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −1.2% in 30 days (Nifty 500: −0.2%).
  • Q1 FY26: Revenue ₹2,101 cr (+16% year on year), EBITDA ₹417 cr (+24% year on year), PAT ₹215 cr (+41% year on year), EBITDA margin 19.9% (+128 bps). Score 70 of 100, Above trend. EBITDA margin rose 128 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −3.5% in 29 days (Nifty 500: +0.7%).
  • Q4 FY25: Revenue ₹2,116 cr, EBITDA ₹403 cr, PAT ₹197 cr, EBITDA margin 19.1%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹2,116 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +22.2% in 29 days (Nifty 500: +1.4%).
  • Q3 FY25: Revenue ₹1,963 cr, EBITDA ₹355 cr, PAT ₹156 cr, EBITDA margin 18.1%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹1,963 cr). Scored once a year-earlier consolidated quarter exists.

Past price moves after results do not indicate future moves. Not a recommendation.

Emcure Pharmaceuticals Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.